Paradigm has results from its Phase 2 hay fever trial pending in six weeks.
ACCESS THE FULL PRESENTATION HERE
View full PAR profile View Profile
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety
Regulatory sign-off fires starting pistol on the commercial launch in Europe, Africa, EU Medical Devices Directive awarded CE IVD certification, molecular diagnostics, Europe, Africa, Sysmex
The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p